Physician profile
Chingleput Ranganathan
NPI 1720063761
$663.24
in general payments reported to CMS, 2019-2025
10 companies · $75.06 in 2025
The $75.06 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2023: $313 · 2024: $166 · 2025: $75.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $255.32 | 2023-2024 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $99.46 | 2023 | Farxiga |
| Novo Nordisk INC | $70.18 | 2021 | |
| Dexcom, INC. | $63.15 | 2024-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $56.18 | 2021-2024 | Minimed 780g |
| Lilly USA, LLC | $32.97 | 2025 | Mounjaro, Zepbound |
| Antares Pharma, INC. | $31.38 | 2024 | Xyosted |
| Beta Bionics, INC. | $21.44 | 2024 | Ilet Bionic Pancreas |
| Abbott Laboratories | $18.33 | 2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $14.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chingleput Ranganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.